RapidAI Raises $75 Million in Financing Round

RapidAI is a leading global company focused on developing Artificial Intelligence (AI) and technology workflow solutions to combat life-threatening neurovascular, cardiac and vascular diseases. The company announced a significant milestone in its growth journey. Secured $75 million in Series C financing with investment led by Vista Credit Partners, a strategic financing partner in the data and technology markets.

The new financing will be used to support platform innovation. And it will allow RapidAI to support more disease states and go-to-market functionalities. What is the goal? To accelerate growth in new regions and product verticals and solidify RapidAI's position as a global leader in clinical AI solutions for life-threatening diseases!

Also See: Online Veterinary Platform Airvet Receives Investment

RapidAI 

RapidAI's AI and workflow technology set the standard in stroke care, the second leading cause of death worldwide. The company's comprehensive portfolio of stroke solutions includes Rapid NCCT Stroke, the first and only FDA-approved medical device capable of detecting suspected intracranial haemorrhage and large vessel occlusion from non-contrast CT imaging. This technology gives hospitals, regardless of size and imaging capabilities, greater access to imaging and decision support. And it addresses a wider patient population. RapidAI has achieved significant milestones on its platform, including analysing more than 10 million scans, publishing in more than 300 peer-reviewed publications and deploying in more than 2,200 hospitals in more than 100 countries. In addition, the company's technology has been used in over 25 clinical trials.

RapidAI CEO Karim Karti emphasised the growing demand for the company's solutions in hospitals as healthcare professionals seek more efficient ways to support clinical decision-making for better patient outcomes. Vista Credit Partners' support and expertise will enable RapidAI to further develop its vision and technological innovation, solidifying its leadership position. It will also enable it to continue to provide cutting-edge clinical AI solutions for life-threatening diseases. David Flannery, President of Vista Credit Partners, highlighted the impact RapidAI has made in advancing patient care for life-threatening diseases. He also expressed his excitement about the partnership and helping the company reach its next stage of growth.